Imagene AI was founded in 2020 with a clear mission to empower physicians and researchers with immediate oncology intelligence to facilitate optimal treatment for more cancer patients.
Harnessing the power of biopsy images to unlock groundbreaking insights, we are transforming cancer diagnostics and research with AI-powered precision oncology.
Imagene’s OISuite, powered by our state-of-the-art pan-cancer vision foundation model, enables the development of diverse applications and accelerates discoveries in oncology. LungOI, our AI-based NSCLC multi-gene test, was developed using our foundation model and provides rapid biomarker profiling, facilitating informed clinical decisions.
Imagene was recognized by Frost & Sullivan for the 2023 "Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis" and won the 2023 Digital Health Award for "Best use of AI."
Our success derives from our cutting-edge technology and a multidisciplinary team of data scientists, biologists, software engineers, and medical experts.
